Free Trial

Context Therapeutics (NASDAQ:CNTX) Given Overweight Rating at Piper Sandler

Context Therapeutics logo with Medical background

Piper Sandler reiterated their overweight rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a report issued on Thursday morning,Benzinga reports. Piper Sandler currently has a $4.00 target price on the stock, down from their prior target price of $4.50.

A number of other equities research analysts also recently weighed in on CNTX. William Blair reissued an "outperform" rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. HC Wainwright reiterated a "buy" rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday, March 21st. Finally, D. Boral Capital reissued a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Context Therapeutics has a consensus rating of "Buy" and an average target price of $5.50.

Check Out Our Latest Report on CNTX

Context Therapeutics Stock Up 1.4%

NASDAQ CNTX traded up $0.01 on Thursday, hitting $0.66. 87,365 shares of the company were exchanged, compared to its average volume of 272,585. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.75. The firm has a 50 day moving average of $0.72 and a two-hundred day moving average of $0.83.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). On average, research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Insider Activity at Context Therapeutics

In related news, CFO Jennifer Lynn Minai-Azary purchased 40,010 shares of the business's stock in a transaction on Friday, June 6th. The shares were purchased at an average price of $0.64 per share, with a total value of $25,606.40. Following the completion of the purchase, the chief financial officer now owns 80,010 shares in the company, valued at $51,206.40. This represents a 100.03% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martin A. Lehr purchased 100,000 shares of Context Therapeutics stock in a transaction dated Monday, June 9th. The stock was bought at an average price of $0.70 per share, with a total value of $70,000.00. Following the acquisition, the chief executive officer now directly owns 920,190 shares of the company's stock, valued at approximately $644,133. This trade represents a 12.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 160,010 shares of company stock worth $107,206 in the last quarter. Corporate insiders own 3.04% of the company's stock.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CNTX. Jane Street Group LLC bought a new position in Context Therapeutics during the 4th quarter worth about $29,000. Citadel Advisors LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth about $31,000. Millennium Management LLC grew its holdings in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after buying an additional 34,835 shares in the last quarter. Shay Capital LLC bought a new position in shares of Context Therapeutics during the fourth quarter worth about $52,000. Finally, Geode Capital Management LLC raised its position in Context Therapeutics by 9.2% in the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock valued at $661,000 after buying an additional 52,830 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

(Get Free Report)

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

Further Reading

Analyst Recommendations for Context Therapeutics (NASDAQ:CNTX)

Should You Invest $1,000 in Context Therapeutics Right Now?

Before you consider Context Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.

While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines